Skip to main content
Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.000
-0.110 (-2.68%)
At close: Feb 27, 2026, 4:00 PM EST
4.010
+0.010 (0.25%)
After-hours: Feb 27, 2026, 7:57 PM EST

Aquestive Therapeutics Revenue

Aquestive Therapeutics had revenue of $12.81M in the quarter ending September 30, 2025, a decrease of -5.43%. This brings the company's revenue in the last twelve months to $43.40M, down -26.32% year-over-year. In the year 2024, Aquestive Therapeutics had annual revenue of $57.56M with 13.80% growth.

Revenue (ttm)
$43.40M
Revenue Growth
-26.32%
P/S Ratio
11.25
Revenue / Employee
$305,613
Employees
142
Market Cap
488.01M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202457.56M6.98M13.80%
Dec 31, 202350.58M2.90M6.09%
Dec 31, 202247.68M-3.15M-6.20%
Dec 31, 202150.83M4.98M10.87%
Dec 31, 202045.85M-6.76M-12.85%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2006 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Emergent BioSolutions 742.90M
Organogenesis Holdings 564.17M
Esperion Therapeutics 303.80M
Ironwood Pharmaceuticals 296.15M
Evolus 285.82M
Akebia Therapeutics 236.20M
Canopy Growth 203.04M
Kamada 174.79M
Revenue Rankings

AQST News

More News